Systemic sclerosis (scleroderma) trials in Germany

In Germany 25 Also abroad 213

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Berlin, Dresden, Essen, Freiburg im Breisgau, Hanover, Kiel, Mainz, Marburg, Münster, Regensburg, Tübingen, Wuppertal
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Not yet taking people in Germany
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Berlin, Dresden, Kiel, Mainz, Marburg, Muenster, Regensburg, Tuebingen, Wuppertal
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 1Taking people
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Where
Augsburg, Cologne, Hanover, Mainz
Age
18 years to 70 years
People
80 worldwide
Run by
CRISPR Therapeutics
See details and how to joinNCT06925542
Phase 1/2Taking people
Controlling Hyperactive Immunity With Long-lived Lymphocytes
Where
Düsseldorf, Erlangen
Age
18 years and over
People
16 worldwide
Run by
Quell Therapeutics Limited
See details and how to joinNCT07473154
Phase 1/2Taking people
Study QEL-005-CLN-01. Phase I/II study of QEL-005 in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
Where
Duesseldorf, Erlangen, Magdeburg
Age
18 years and over
People
8 worldwide
Run by
Quell Therapeutics Limited
See details and how to join2025-523971-46-00 · EU 2025-523971-46-00
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Bad Bramstedt, Berlin, Dresden, Gommern, Hanover, Heidelberg, Luebeck, Mainz, Muenster, Oberhausen, Tuebingen
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 1Not yet taking people in Germany
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Berlin, Erlangen, Magdeburg, Würzburg
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 2Taking people
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial
Where
Leipzig
Age
18 years and over
People
5
Run by
Universitaet Leipzig
See details and how to join2025-523061-22-00 · EU 2025-523061-22-00
Phase 1Not yet taking people in Germany
A Study of PRO-203 in Healthy Volunteers and Participants with Systemic Sclerosis
Where
Duesseldorf, Frankfurt Am Main, Jena, Luebeck, Munich
Age
18 years to 64 years
People
9
Run by
Prolium Bioscience Inc.
See details and how to join2026-526659-70-00 · EU 2026-526659-70-00
Phase 3Not yet taking people in Germany
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Where
Berlin, Cologne, Erlangen, Leipzig, Munich, Wuerzburg
Age
16 years and over
People
92 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Cologne, Duesseldorf, Mainz, Minden, Tuebingen
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
Phase 1Taking people
Treatment of patients with autoantibody-positive autoimmune diseases and severe interstitial lung fibrosis with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - a single center Phase I/II clinical trial (HD-CAR-ILD-1)
Where
Heidelberg
Age
18 years and over
People
10
Run by
Universitaetsklinikum Heidelberg AöR
See details and how to join2024-519592-26-00 · EU 2024-519592-26-00
Phase 2Taking people
Platform Clinical Study for Conquering Scleroderma
Where
Duesseldorf, Erlangen, Luebeck, Mainz, Munich
Age
18 years and over
People
400 worldwide
Run by
Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00
Phase 1Taking people
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Where
Augsburg, Cologne, Frankfurt Am Main, Hanover, Mainz
Age
18 years and over
People
51 worldwide
Run by
CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 · EU 2024-518528-54-00
Phase 1/2Not yet taking people in Germany
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Where
Tuebingen
Age
18 years and over
People
36
Run by
Universitaetsklinikum Tuebingen AöR
See details and how to join2024-519491-60-00 · EU 2024-519491-60-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bonn, Munich
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Berlin, Dresden, Duesseldorf, Hamburg, Kiel
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 2Not yet taking people in Germany
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)
Where
Berlin, Dresden, Erlangen, Freiburg im Breisgau, Oberhausen, Tuebingen
Age
18 years and over
People
78
Run by
Charite Universitaetsmedizin Berlin KöR
See details and how to join2025-524435-39-00 · EU 2025-524435-39-00
Phase 1/2Taking people
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL
Where
Erlangen
Age
18 years and over
People
12
Run by
Universitaetsklinikum Erlangen AöR
See details and how to join2024-519532-16-00 · EU 2024-519532-16-00
No phaseTaking people
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Where
Hamburg
Age
Up to 18 years
People
20 worldwide
Run by
Meyer Children's Hospital IRCCS
See details and how to joinNCT07348263
Phase 2/3Taking people
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Where
Berlin, Bochum, Hamburg, Hanover
Age
18 years and over
People
70 worldwide
Run by
Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00
Phase 1/2Taking people
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Where
Erlangen
Age
18 years and over
People
24
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06347718 · EU 2024-516819-24-00
No phaseEnrolling by invitation
Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
Where
Hanover
Age
18 years to 99 years
People
1,000 worldwide
Run by
Royal Brompton & Harefield NHS Foundation Trust
See details and how to joinNCT06472362
No phaseTaking people
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
Where
Bonn
Age
18 years and over
People
120
Run by
University of Bonn
See details and how to joinNCT07150000